Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, T-Cell, Peripheral × tipifarnib × 1 year × Clear all

Status

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Neuroblastoma 3 Wilms Tumor 2 Sarcoma, Ewing 2 Sarcoma 2 Rhabdomyosarcoma 2 Rhabdoid Tumor 2 Osteosarcoma 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Medulloblastoma 2 Lymphoma, Non-Hodgkin 2 Histiocytosis, Langerhans-Cell 2 Hepatoblastoma 2 Glioma 2 Ependymoma 2 Xanthogranuloma, Juvenile 1 Thyroid Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Pheochromocytoma 1 Melanoma 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma 1 Histiocytic Sarcoma 1 Hereditary Sensory and Autonomic Neuropathies 1 Head and Neck Neoplasms 1 Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 11 Prednisone 8 Doxorubicin 8 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 7 Vincristine 6 Brentuximab Vedotin 5 Azacitidine 5 fludarabine 4 Gemcitabine 4 Etoposide 4 romidepsin 3 pembrolizumab 3 belinostat 3 Dexamethasone 3 Biopsy 3 10-propargyl-10-deazaaminopterin 3 tazemetostat 2 ruxolitinib 2 Lenalidomide 2 Bendamustine Hydrochloride 2 venetoclax 1 tislelizumab 1 tipifarnib 1 thymoglobulin 1 sodium-iodide symporter 1 selinexor 1 relatlimab 1 pomalidomide 1 ixazomib 1 ivarmacitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04809233 2025-06-04

Expanded Access to Tipifarnib

Kura Oncology, Inc.

Lymphoma, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon ⚡